Dyadic International Inc. (NASDAQ:DYAI) Short Interest Down 76.2% in June

Posted by Stanley Muller on Jun 27th, 2026

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totaling 148,312 shares, a decline of 76.2% from the May 31st total of 622,465 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average trading volume of 188,919 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.00.

Get Our Latest Report on DYAI

Hedge Funds Weigh In On Dyadic International

Large investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its holdings in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. Marathon Capital Management acquired a new stake in shares of Dyadic International in the 3rd quarter worth $41,000. Geode Capital Management LLC grew its stake in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new position in Dyadic International during the 3rd quarter worth $190,000. Finally, Apis Capital Advisors LLC acquired a new position in Dyadic International during the 3rd quarter valued at about $1,817,000. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Stock Up 8.1%

Shares of Dyadic International stock opened at $0.80 on Friday. The firm’s 50 day moving average price is $0.76 and its 200-day moving average price is $0.83. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. Dyadic International has a 52-week low of $0.65 and a 52-week high of $1.35. The company has a market cap of $29.19 million, a P/E ratio of -3.48 and a beta of 1.17.

Dyadic International (NASDAQ:DYAI – Get Free Report) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The firm had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. On average, sell-side analysts predict that Dyadic International will post 0.13 EPS for the current fiscal year.

Dyadic International Company Profile

(Get Free Report)

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.